First-Line Treatment Study of Anti-PD-1PD-L1 and Anti-Angiogenic Drugs for Unresectable Liver Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining anti-PD-1PD-L1 immunotherapy with anti-angiogenic drugs as a first treatment for people with unresectable hepatocellular carcinoma HCC, a type of liver cancer that cannot be removed by surgery. This multicenter, randomized, open-label phase 2 clinical trial compares three treatment combinations to find the best approach for this serious condition. Participants receive one of three drug combinations. The first group gets Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally daily. The second group receives Adebrelimab 1200mg intravenously plus Bevacizumab 15mgkg intravenously every 3 weeks. The third group is treated with Camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally daily. These treatments are given as first-line therapy, meaning they are the initial systemic treatment for advanced HCC. Throughout the study, participants are closely monitored for overall survival at 12 months and other outcomes such as response rates, disease control, duration of response, time to response, progression-free survival, and safety using standard criteria. The study lasts up to about 3 years, during which patients undergo regular assessments to track cancer progression, side effects, and overall health. This comprehensive monitoring helps researchers understand how well each treatment works and its safety profile.

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC